Scott & Selber Inc. Takes Position in Allergan PLC (AGN)
Scott & Selber Inc. bought a new stake in shares of Allergan PLC (NYSE:AGN) during the second quarter, according to its most recent disclosure with the SEC. The fund bought 6,188 shares of the company’s stock, valued at approximately $1,430,000.
Other large investors have also made changes to their positions in the company. Barnett & Company Inc. purchased a new stake in shares of Allergan PLC during the first quarter valued at $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Allergan PLC during the second quarter valued at $125,000. Trust Co. of Vermont raised its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Integrated Investment Consultants LLC raised its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Finally, Trust Department MB Financial Bank N A raised its stake in shares of Allergan PLC by 77.4% in the second quarter. Trust Department MB Financial Bank N A now owns 653 shares of the company’s stock valued at $198,000 after buying an additional 285 shares during the period. 85.20% of the stock is owned by hedge funds and other institutional investors.
Shares of Allergan PLC (NYSE:AGN) traded up 0.43% during trading on Wednesday, reaching $228.91. The company’s stock had a trading volume of 2,985,325 shares. The company has a 50 day moving average of $237.35 and a 200-day moving average of $237.14. The stock has a market cap of $90.64 billion, a price-to-earnings ratio of 21.79 and a beta of 0.81. Allergan PLC has a 12-month low of $195.50 and a 12-month high of $322.68.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the business posted $4.41 earnings per share. The firm’s revenue was up 1.0% on a year-over-year basis. Analysts forecast that Allergan PLC will post $14.00 EPS for the current year.
Several brokerages recently weighed in on AGN. Deutsche Bank AG set a $278.00 price objective on Allergan PLC and gave the stock a “buy” rating in a report on Saturday. Mizuho reissued a “hold” rating and issued a $232.00 price objective on shares of Allergan PLC in a report on Monday, July 11th. RBC Capital Markets reissued an “outperform” rating and issued a $300.00 price objective (down previously from $307.00) on shares of Allergan PLC in a report on Wednesday, August 10th. Piper Jaffray Cos. set a $227.00 price objective on Allergan PLC and gave the stock a “hold” rating in a report on Tuesday, August 9th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Allergan PLC in a report on Wednesday, June 29th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Allergan PLC presently has a consensus rating of “Buy” and an average price target of $302.23.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.